State Street Corp Arcutis Biotherapeutics, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 5,641,631 shares of ARQT stock, worth $75.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,641,631

Previous 5,134,843 9.87%

Holding current value

$75.6 Million

Previous $47.8 Million 9.87%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$8.32 - $11.0 $4.22 Million - $5.57 Million	506,788 Added 9.87%	5,641,631 $52.5 Million
Q2 2024 Aug 14, 2024	SELL	$7.24 - $12.53 $26.4 Million - $45.7 Million	-3,649,195 Reduced 41.54%	5,134,843 $47.8 Million
Q1 2024 May 15, 2024	BUY	$3.25 - $11.77 $23.6 Million - $85.4 Million	7,258,993 Added 475.99%	8,784,038 $87 Million
Q4 2023 Feb 14, 2024	SELL	$1.84 - $4.82 $5.22 Million - $13.7 Million	-2,835,762 Reduced 65.03%	1,525,045 $4.93 Million
Q3 2023 Nov 14, 2023	SELL	$5.31 - $10.98 $4.59 Million - $9.5 Million	-865,202 Reduced 16.56%	4,360,807 $23.2 Million
Q2 2023 Aug 14, 2023	BUY	$7.51 - $15.0 $12.1 Million - $24.2 Million	1,611,228 Added 44.57%	5,226,009 $49.8 Million
Q1 2023 May 15, 2023	SELL	$10.23 - $17.14 $660,898 - $1.11 Million	-64,604 Reduced 1.76%	3,614,781 $39.8 Million
Q4 2022 Feb 14, 2023	BUY	$13.96 - $20.4 $14.3 Million - $20.9 Million	1,024,150 Added 38.57%	3,679,385 $54.5 Million
Q3 2022 Nov 15, 2022	BUY	$17.85 - $26.95 $22.5 Million - $33.9 Million	1,258,810 Added 90.15%	2,655,235 $50.7 Million
Q2 2022 Aug 15, 2022	BUY	$16.33 - $22.2 $3.38 Million - $4.59 Million	206,925 Added 17.4%	1,396,425 $29.8 Million
Q1 2022 May 16, 2022	BUY	$14.38 - $22.79 $995,009 - $1.58 Million	69,194 Added 6.18%	1,189,500 $22.9 Million
Q4 2021 Feb 14, 2022	BUY	$14.98 - $25.5 $1.21 Million - $2.07 Million	81,093 Added 7.8%	1,120,306 $23.2 Million
Q3 2021 Nov 15, 2021	SELL	$19.28 - $27.1 $2.18 Million - $3.07 Million	-113,269 Reduced 9.83%	1,039,213 $24.8 Million
Q2 2021 Aug 16, 2021	BUY	$24.42 - $34.75 $4.51 Million - $6.41 Million	184,500 Added 19.06%	1,152,482 $31.5 Million
Q1 2021 May 17, 2021	BUY	$24.47 - $36.98 $3.16 Million - $4.77 Million	128,960 Added 15.37%	967,982 $28 Million
Q4 2020 Feb 16, 2021	BUY	$17.82 - $31.73 $10.2 Million - $18.2 Million	573,588 Added 216.09%	839,022 $23.6 Million
Q3 2020 Nov 10, 2020	BUY	$23.44 - $32.28 $1.85 Million - $2.55 Million	78,854 Added 42.26%	265,434 $7.78 Million
Q2 2020 Aug 14, 2020	BUY	$24.48 - $36.56 $465,658 - $695,444	19,022 Added 11.35%	186,580 $5.64 Million
Q1 2020 May 11, 2020	BUY	$18.5 - $36.9 $3.1 Million - $6.18 Million	167,558 New	167,558 $4.99 Million

Others Institutions Holding ARQT

# of Institutions

197

Shares Held

129M

Call Options Held

738K

Put Options Held

82K

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $807M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Arcutis Biotherapeutics, Inc. Transaction History